Literature DB >> 19634715

Anti-iL-10 mAb protection against experimental visceral leishmaniasis via induction of Th1 cytokines and nitric oxide.

Surajit Bhattacharjee, Gaurav Gupta, Parna Bhattacharya, Anupam Adhikari, Suchandra Bhattacharya Majumdar, Subrata Majumdar.   

Abstract

Visceral leishmaniasis is characterized by severe immune suppression of the host. This suppression of the host immune system is primarily mediated by the immunosuppressive cytokine Interleukin-10 (IL-10), whose levels are significantly upregulated during leishmaniasis. This immune suppression is reflected at the level of T-cell dysfunction and abrogation of leishmaniacidal molecules along with a dampened Th1 cytokine response. In the present study, we showed in vivo neutralization of IL-10 by administration of anti IL-10 monoclonal antibodies (mAb) could confer protection against leishmanial pathogenesis. This protective response was primarily mediated by a strong induction of T cell proliferation along with a Th1 biased cytokine response which was further aided by the generation of, leishmanicidal molecules, nitric oxide.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19634715

Source DB:  PubMed          Journal:  Indian J Exp Biol        ISSN: 0019-5189            Impact factor:   0.818


  7 in total

1.  Augmentation of antileishmanial efficacy of miltefosine in combination with tuftsin against experimental visceral leishmaniasis.

Authors:  Nishi Shakya; Shraddha A Sane; Wahajul Haq; Suman Gupta
Journal:  Parasitol Res       Date:  2012-03-06       Impact factor: 2.289

Review 2.  Whole blood assay and visceral leishmaniasis: Challenges and promises.

Authors:  Om Prakash Singh; Shyam Sundar
Journal:  Immunobiology       Date:  2014-01-31       Impact factor: 3.144

Review 3.  Immunoregulation in human American leishmaniasis: balancing pathology and protection.

Authors:  K J Gollob; A G Viana; W O Dutra
Journal:  Parasite Immunol       Date:  2014-08       Impact factor: 2.280

4.  Th1-biased immunomodulation and therapeutic potential of Artemisia annua in murine visceral leishmaniasis.

Authors:  Mohammad Islamuddin; Garima Chouhan; Abdullah Farooque; Bilikere S Dwarakanath; Dinkar Sahal; Farhat Afrin
Journal:  PLoS Negl Trop Dis       Date:  2015-01-08

5.  Interleukin-10 and Interferon-γ Levels in Patients with Cutaneous Leishmaniasis Treated with Cryotherapy.

Authors:  Farhad Handjani; Saeed Reza Yousef; Nasrin Saki; Nasrin Hamidizadeh
Journal:  Iran J Med Sci       Date:  2017-09

6.  EB1-3 Chain of IL-35 Along With TGF-β Synergistically Regulate Anti-leishmanial Immunity.

Authors:  Mohammad Asad; Abdus Sabur; Mohammad Shadab; Sonali Das; Mohd Kamran; Nicky Didwania; Nahid Ali
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

Review 7.  Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.

Authors:  Wim Adriaensen; Thomas P C Dorlo; Guido Vanham; Luc Kestens; Paul M Kaye; Johan van Griensven
Journal:  Front Immunol       Date:  2018-01-12       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.